Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.

J Immunother Cancer · 2021 · PMC8126291 · PMID 33986126

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Importantly, the results for MGR and OS remained highly significant after exclusion of mucosal and uveal melanomas ( online supplemental figure 3 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.